242 related articles for article (PubMed ID: 18670368)
1. Atrial-selective sodium channel blockers: do they exist?
Burashnikov A; Antzelevitch C
J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
[TBL] [Abstract][Full Text] [Related]
2. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
Antzelevitch C; Burashnikov A
J Electrocardiol; 2009; 42(6):543-8. PubMed ID: 19698954
[TBL] [Abstract][Full Text] [Related]
3. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
[TBL] [Abstract][Full Text] [Related]
4. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
5. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Burashnikov A; Belardinelli L; Antzelevitch C
J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
[TBL] [Abstract][Full Text] [Related]
6. Atrial-selective sodium channel block for the treatment of atrial fibrillation.
Burashnikov A; Antzelevitch C
Expert Opin Emerg Drugs; 2009 Jun; 14(2):233-49. PubMed ID: 19466903
[TBL] [Abstract][Full Text] [Related]
7. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.
Antzelevitch C; Burashnikov A
Ann N Y Acad Sci; 2010 Feb; 1188():78-86. PubMed ID: 20201889
[TBL] [Abstract][Full Text] [Related]
8. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
Aguilar-Shardonofsky M; Vigmond EJ; Nattel S; Comtois P
Biophys J; 2012 Mar; 102(5):951-60. PubMed ID: 22404917
[TBL] [Abstract][Full Text] [Related]
9. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
Burashnikov A; Belardinelli L; Antzelevitch C
Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
[TBL] [Abstract][Full Text] [Related]
11. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
[TBL] [Abstract][Full Text] [Related]
12. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
13. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
[TBL] [Abstract][Full Text] [Related]
14. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.
Sicouri S; Burashnikov A; Belardinelli L; Antzelevitch C
Circ Arrhythm Electrophysiol; 2010 Feb; 3(1):88-95. PubMed ID: 19952329
[TBL] [Abstract][Full Text] [Related]
15. Can inhibition of IKur promote atrial fibrillation?
Burashnikov A; Antzelevitch C
Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
[TBL] [Abstract][Full Text] [Related]
16. Atrial selectivity of antiarrhythmic drugs.
Ravens U; Poulet C; Wettwer E; Knaut M
J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
[TBL] [Abstract][Full Text] [Related]
17. Role of late sodium channel current block in the management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches for pharmacological management of atrial fibrillation.
Ehrlich JR; Nattel S
Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
